John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
John Barbieri, M.D., MBA, is one of the more 17,000 dermatologists and others attending the American Academy of Dermatology’s annual meeting this weekend in San Diego.
Barbieri, an assistant professor at Harvard Medical School, says he is looking forward to the fresh troves of data and the connecting with colleagues.
“I love seeing the new trial data as it comes out, and the late breaking research sessions are a good place to find those,” Barbieri said in a recent interview. “I also find that AAD is a great time to connect with colleagues. I think that's one of the best parts of this meeting is being able to see all of our colleagues in dermatology to think about how we can collaborate, to think about how we can move the field forward together.”
Barbieri specializes in inflammatory skin disease such as acne, rosacea, psoriasis and atopic dermatitis. He is the director of the Advanced Acne Therapeutics Clinic at the Harvard-affiliated Brigham and Women’s Hospital in Boston and is the co-chair of the academy’s acne guidelines work group.
He is speaking at four sessions at the meeting, which started today and ends on Tuesday. The sessions he is speaking are titled Great Care for Common Conditions: Combining Evidence and Cost Effectiveness; JAAD [Journal of the American Academy of Dermatology] game changers; Controversies in Acne and Rosacea; and Translating Evidence Into Practice: Acne Guidelines and Beyond.
Experts Explore Causes and Care for Chronic Itch
April 22nd 2025In a recent discussion with Managed Healthcare Executive, three leading dermatologists and itch experts—Shawn Kwatra, M.D., Brian Kim, M.D., and Gil Yosipovitch, M.D.—shared where the science is going, what’s holding it back and how the healthcare system can better support patients.
Read More
Insights Into Chronic Itch From Shawn Kwatra, M.D.
April 15th 2025A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.
Read More
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, according to study findings presented at the 2025 American Academy of Dermatology annual meeting.
Read More